Innova Biosciences Receives Investment to Increase Sales Activities

Published: Oct 01, 2009

Innova Biosciences (Cambridge, UK), a pioneer in the field of antibody labeling and inventor of the World’s easiest to use antibody labeling kit- Lightning-Link™, is pleased to announce a further cash investment into the business. Recently appointed Board member, Tim Bernard (formally Managing Director of AbD Serotec and CEO of Pivotal Scientific) has invested an undisclosed sum in the company. The new funds will be used to strengthen Innova’s sales and marketing activities.

Commenting on the investment Tim Bernard mentioned – ‘Shortly after the joining the Board, it became apparent that the company had an innovative product portfolio with a large customer base. Based upon my own experiences, such opportunities rarely come along and therefore I decided to invest in the business. I look forward to working with the Innova team to successfully grow the company.’

Dr Nick Gee, CEO of Innova Biosciences - ‘We are delighted to accept Tim’s investment, which will allow Innova to expand its sales and marketing operations and to build on the impressive growth achieved so far in 2009.’

About the company: Innova Biosciences is a growing, dynamic business, based in Cambridge, UK. At the core of Innova’s business is the Lightning-Link™, an innovative technology that simplifies antibody labeling for use in R&D applications, drug discovery and diagnostics. The expanding Lightning-Link™ portfolio currently consists of 44 individual products and is sold to research laboratories in over 30 countries around the world.

Back to news